# Phase I Study of MT1011 Injection in Healthy Subjects

> **NCT07024160** · PHASE1 · RECRUITING · sponsor: **Shaanxi Micot Pharmaceutical Technology Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation

## Interventions

- **DRUG:** MT1011
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07024160
- **Lead sponsor:** Shaanxi Micot Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-25
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07024160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07024160, "Phase I Study of MT1011 Injection in Healthy Subjects". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT07024160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*